



Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Sabine E. Grimm¹ · Willem Witlox¹ · Robert Wolff² · Annette Chalker² · Mickael Hiligsmann³ · Ben Wijnen¹ · Charlotte Ahmadu² · Steve Ryder² · Nigel Armstrong² · Steven Duffy² · Isabel Syndikus⁴ · Jos Kleijnen^{2,3} · Manuela A. Joore¹

Published online: 1 April 2022
© The Author(s) 2022

Correction to: *Pharmacoeconomics* (2021) <https://doi.org/10.1007/s40273-021-01098-3>

The following sentence has been added to the end of the abstract of the original online version

“This decision was subsequently appealed, and an appeal decision has been reached.”

In the article, Sect. 3.2 Critique of Clinical Effectiveness Evidence and Interpretation, 5th para, 3rd and 4th sentences should be read as

“For example, the company did not provide a description of the methods used for the matching, except the process of selection of variables for which adjustment is required. Based on the provided information, it appeared that data were available for only three of the variables (disease type, number of prior systemic therapies, type of prior systemic therapies) that were considered in the analysis of the HES

data and only one variable (disease type) was chosen for matching.”

In the article, Sect. 3.3 Cost-Effectiveness Evidence Submitted by the Company, 14th para, final sentence should be removed.

“The impact of AEs on HRQoL was, however, not included in the model.”

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s40273-021-01098-3>.

✉ Sabine E. Grimm
sabine.grimm@mumc.nl

¹ Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), P. Debye laan 25, PO Box 5800, 6202 AZ Maastricht, The Netherlands

² Kleijnen Systematic Reviews Ltd, York, UK

³ Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands

⁴ The Clatterbridge Cancer Centre National Health Service (NHS) Foundation Trust, Wirral, UK